See the DrugPatentWatch profile for sarclisa

Sarclisa (isatuximab-irfc), developed by Sanofi and Regeneron, is a CD38 antibody approved for the treatment of multiple myeloma in combination with pomalidomide and dexamethasone. The drug received approval from the U.S. Food and Drug Administration (FDA) in March 2020 [1]. CD38 antibodies work by targeting CD38 proteins, which are highly expressed on the surface of multiple myeloma cells [2].

When comparing Sarclisa to other CD38 antibodies, such as Darzalex (daratumumab) and Fasenra (benralizumab), there are differences in terms of their clinical trial results, mechanisms of action, and administration.

1. Clinical trial results:
- Sarclisa, in combination with pomalidomide and dexamethasone, showed a significant improvement in progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma, compared to pomalidomide and dexamethasone alone [1].
- Darzalex, when used in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone, has demonstrated improved PFS and overall response rates (ORR) in patients with newly diagnosed or relapsed/refractory multiple myeloma [3].
- Fasenra, although also a CD38 antibody, is primarily used for the treatment of severe asthma and has not been studied in multiple myeloma [4].

2. Mechanisms of action:
- Sarclisa and Darzalex are both monoclonal antibodies that bind to CD38 on multiple myeloma cells, inducing antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) [1][3].
- Fasenra, on the other hand, is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, which primarily targets eosinophils in asthma patients [4].

3. Administration:
- Sarclisa is administered intravenously (IV) at a dose of 10 mg/kg once a week for four weeks, followed by every two weeks [1].
- Darzalex is administered intravenously (IV) or subcutaneously (SC) at a dose of 16 mg/kg once a week for three weeks, followed by once every three weeks [3].
- Fasenra is administered subcutaneously (SC) at a dose of 30 mg every four weeks for the first three doses, followed by every eight weeks [4].

In summary, Sarclisa has demonstrated its effectiveness in treating relapsed/refractory multiple myeloma in combination with pomalidomide and dexamethasone. While Darzalex has also shown positive results in multiple myeloma treatment, Fasenra is primarily used for asthma and has not been studied in multiple myeloma. Differences in mechanisms of action and administration further distinguish these CD38 antibodies.

Sources:
[1] FDA. (2020). FDA approves new treatment for relapsed or refractory multiple myeloma. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-new-treatment-relapsed-or-refractory-multiple-myeloma>
[2] DrugPatentWatch.com. (n.d.). Sarclisa (isatuximab-irfc). <https://www.drugpatentwatch.com/drugs/sarclisa>
[3] Darzalex. (2021). Highlights of prescribing information. <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/darzalex-prescribing-information.pdf>
[4] Fasenra. (2021). Highlights of prescribing information. <https://www.fda.gov/media/108991/download>